ErSo - Trials on Mice have eradicated Metastatic Breast Cancer Cells - we need HUMAN trials now ...
Beating breast cancer Estrogen receptor–positive breast cancer is the most common type of breast cancer and, in its metastatic form, is currently incurable. In a new study, Boudreau et al. describe a compound, ErSO, that can activate the unfolded protein response, resulting in necrosis of human breast cancer cell lines in vitro. In vivo, this treatment induced complete regression of cell line and patient-derived orthotopic and metastatic breast cancer xenografts in mice. The authors showed that this treatment was well tolerated in mice, rats, and dogs and could provide a new avenue of intervention for this deadly disease. Abstract Metastatic estrogen receptor α (ERα)–positive breast cancer is presently incurable. Seeking to target these drug-resistant cancers, we report the discovery of a compound, called ErSO, that activates the anticipatory unfolded protein response (a-UPR) and induces rapid and selective necrosis of ERα-positive breast cancer cell lines in vitro. We then tested ErSO in vivo in several preclinical orthotopic and metastasis mouse models carrying different xenografts of human breast cancer lines or patient-derived breast tumors. In multiple orthotopic models, ErSO treatment given either orally or intraperitoneally for 14 to 21 days induced tumor regression without recurrence. In a cell line tail vein metastasis model, ErSO was also effective at inducing regression of most lung, bone, and liver metastases. ErSO treatment induced almost complete regression of brain metastases in mice carrying intracranial human breast cancer cell line xenografts. Tumors that did not undergo complete regression and regrew remained sensitive to retreatment with ErSO. ErSO was well tolerated in mice, rats, and dogs at doses above those needed for therapeutic responses and had little or no effect on normal ERα-expressing murine tissues. ErSO mediated its anticancer effects through activation of the a-UPR, suggesting that activation of a tumor protective pathway could induce tumor regression. https://news.illinois.edu/view/6367/339688859?fbclid=IwAR0h1IknctZG6-YwnsbeAm-4Q_Yi9piOYfUPc7z1ymYl-NIeZXH5W16zjUE#image-2 One lady actually wrote to one of the reseachers and he said to contact Bayer directly, as they bought the "rights" and as yet, they haven't scheduled clinical trials. I am sure that if controlling oestrogen was a major part of controlling Prostate or Testicular Cancer, they'd be RACING to get this to market ..... WE ALL NEED TO WRITE TO BAYER! Copy & Send this post to your Onc too!! Here is a Bayer contact the researcher gave: rose.talarico@bayer.com Hopefully, if LOTS OF PEOPLE from all around the world WRITE to Bayer - they may 'run with it' .... but the facts are, if something like this isn't profitable enough to them - it might get shelved! :(Q&A – TRIPLE NEGATIVE BREAST CANCER on Tuesday 24th October from 4:30-6pm (AEDT).
Register for the Q&A on Triple Negative Breast Cancer (Submit a question.) https://www.breastcancertrials.org.au/news/qa-events/qa-triple-negative-breast-cancer/ Triple negative breast cancer accounts for approximately 15% of all breast cancers. As the name suggests, triple negative breast cancer does not have any of the three receptors that are commonly found on breast cancer cells – oestrogen, progesterone and HER2 receptors. Anyone can be diagnosed with triple negative breast cancer but it occurs more often in younger patients who are pre-menopausal or under 50 years of age. People with a BRCA1 gene mutation also have a higher risk of this type of breast cancer. Triple negative breast cancer is a more aggressive type of tumour, with a faster growth rate, a higher risk of spreading to other parts of the body (metastasis) and of recurrence either in the breast or elsewhere. Because it does not have any of the more common receptors that can be targeted by medications, such as hormone and HER2-blocking drugs, it has fewer treatment options available. Standard treatment of early stage triple negative breast cancer typically includes chemotherapy, surgery and in many cases a course of radiotherapy. Often chemotherapy treatment is given prior to breast surgery (neoadjuvant chemotherapy), as it can effectively reduce the size of the breast cancer while providing useful information about the effectiveness of the treatment being given. Breast Cancer Trials has been researching new and better treatments for triple negative breast cancer. The CHARIOT clinical trial examined the addition of dual immunotherapy to standard chemotherapy and showed promising results in patients with treatment resistant, early-stage triple negative breast cancer. The Neo-N clinical trial is investigating whether using an immunotherapy drug together with chemotherapy, is safe and effective in treating breast cancer before surgery. Results of this study are expected later this year. Join our panel of experts as we explore triple negative breast cancer. We’ll hear firsthand from women who have a history of this type of cancer, and from world-leading researchers on the latest in research and clinical trials to improve treatments and patient outcomesA new clinical Trial in Australia - Ember-4 (Endocrine/AI alternative) - has anyone heard of it?
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (These links show other BC Trials that are currently 'open' in Australia - but only the WA page mentions Ember-4 ... ) https://www.breastcancertrials.org.au/research/open-clinical-trials/ https://bcrc-wa.com.au/open-clinical-trials/ https://trials.cancervic.org.au/search/ (Put Breast Cancer in the search area) https://www.australianclinicaltrials.gov.au/anzctr-search-results?search_text=breast%2Bcancer&condition_category=all&condition_code=all&recruitment_status=Recruitingðics_approval=Yes Not sure if this will help anyone - it is a different form of AI they are 'testing' ... I found this info on the Ember-4 trial on one of the Facebook BC sites ..... (BTW, this is NOT written by me and does not relate to me in any way .. ) (SERDs are an important endocrine therapy used to treat ER-positive breast cancer. Parenteral SERD Fulvestrant has been approved and used in the treatment of metastatic ER-positive breast cancer for the last 2 decades.) From a Facebook BC Post: Is anyone else on the Ember-4 trial? I found out yesterday that I was selected in the trial to get Ilumestrant (a new SERD that replaces your AI) so that is quite exciting, but I ended up with horrible diarrhoea yesterday after taking my first dose, so hopefully that is not a side-effect that continues… Ilumestrant is a Selective Estrogen Receptor Degrader (SERD) that you take instead of taking an oestrogen blocker or aromatase inhibitor… it degrades the estrogen receptor sites in the cancer cells rather than blocking your oestrogen, so it allows your body to have some oestrogen and hopefully less joint aches and pains etc… An interesting thing about it is that you must fast for one hour before you take it, and for two hours after you take it. This will not be an issue for me, but I imagine it could be hard in some situations.Breast Cancer & Fertility - a Q&A Webinar - 20th Feb, 5 - 6.30pm
For those interested in Breast Cancer & Fertility - register for this webinar on Feb 20th. Around 4,000 women in Australia under the age of 45 are diagnosed with breast cancer each year. For those in their childbearing years decisions about treatment need to consider fertility, as treatments such as chemotherapy and hormone therapy may induce premature menopause and can reduce a woman’s chance of having children. Moderated by author and journalist Annabel Crabb, the panel of experts will discuss fertility preservation options, informed decision making, and the latest research – including the POEMS clinical trial, which your support has made possible. https://www.breastcancertrials.org.au/news/qa-events/qa-breast-cancer-and-fertility/
Three dimensional tissue engineering with biodegradable breast scaffolds post mastectomy
Hello all, The above is being researched by Queensland University Hospital with Prof Dietmar Hutmacher as the head. It will be a great alternative to breast implants as it replaced by regenerating tissue rather than replacing it. I am wondering if anyone is in the know about upcoming clinical trials? I noticed it in a couple of stories in daily newspaper and media, six years ago when I had my mastectomy and sentinal lobe clearance. I was hopeful when I saw it and held off having any of the current recon. surgeries. All the best and it's onwards and upwards, MariaTriple Negative Vaccine hopes to eliminate the disease - we need these trials in Australia NOW!
This is in the UK newspaper today - hopefully these trials will be in Australia SOON .... Maybe Ask your Onc about this ..... the sooner it starts here, the better. Triple Negative Breast cancer vaccine 'could eliminate disease by 2030' : 15 women who survived aggressive tumours are still in remission up to five years later after receiving experimental shot — now doctors believe a cure is in sight https://www.dailymail.co.uk/health/article-12140391/Breast-cancer-vaccine-eliminate-form-disease-seven-YEARS.html and another report from Dec 2022 https://www.dailymail.co.uk/health/article-11400715/Three-cancer-patients-cured-experimental-vaccine-100x-cheaper-rival-shots.htmlDr Liz O'Riordan talks about her surgeries & aftermath - A UK Breast Surgeon with Breast Cancer
Dr Liz O'Riordan was diagnosed with breast cancer some years after qualifying as a breast cancer surgeon & realised that whilst she knew some of the physical effects of Breast Cancer surgery - she really was not prepared for the psychological (and indeed actual physical limitations) that she experienced, once she'd had her own surgery, chemo, rads etc - she also suffered from extreme cording that restricted her arm movement. Eventually, after a recurrence and more surgery, it prevented her from continuing as a Breast Surgeon. This is a more recent write up : https://www.nzherald.co.nz/lifestyle/dr-liz-oriordan-im-a-breast-cancer-surgeon-this-is-what-surviving-cancer-myself-taught-me/GWGO5EWTRNFAHB7MLHU5SGPTIM/ In her own 'blog' - she writes candidly - from her own diagnosis, surgery, chemo, tabs & treatment overall with all the same fears and side effects that many of us have experienced .... Read her personal story here (then click on her 'blog': http://liz.oriordan.co.uk/ You can follow her on Instagram too https://www.instagram.com/oriordanliz - work your way thru her videos ..... they are authentic & helpful She has announced a New trial in the UK, attempting to identify younger women with higher risk of breast cancer BEFORE diagnosis - particularly those with dense breast tissue .... leading to earlier intensive testing before the 'normal age' of 40 https://www.instagram.com ; /p/Ct_-RRUINgJ/. (copy & join these 2 parts of the link, to see it as it won't load here.) Nina Lopez (who Liz interviews in one of the videos - add 'this link' after the '.instagram.com bit ... p/Ct2ESwoIkwn/) who talks about HER triple Negative BC here: https://www.the-c-list.com/stories/nina-lopez-39-shares-her-story-of-motherhood-treatment-and-resilience-as-she-lives-with-secondary-breast-cancer And below, are some of the subjects that she covers on Instagram ..My Care - Understanding Access to Clinical Trials
Hi members, As we round out October breast Cancer Awareness Month, BCNA have highlighted key aspects of the optimal breast cancer care. The aim was to raise awareness in the community, the health sector and amongst the BCNA network about what optimal care means. The final key area relating to the theme of 'understanding my care' of the Optimal care pathways for people with breast cancer is: 'Access to Clinical Trials' Clinical trials are the foundation for improved cancer outcomes. They allow new treatments to be tested and can offer patients access to potentially more effective options than would otherwise be available to them. There are also clinical trials for different types of supportive care. Clinical trials won’t be suitable for everyone but treating specialists and multidisciplinary teams should discuss relevant clinical trials that may be available to you. This includes how these trials can be accessed, which is important for rural and regional patients who might live long distances for trial sites. It’s important to know that whether or not you are participating in a clinical trial, you will always be receiving the very best standard of treatment. You can refer to the articles in My Journey Clinical trials for early breast cancer Clinical trials for metastatic breast cancer Clinical trials and DCIS for more information regarding clinical trials. For further information regarding the optimal care pathway head to our website https://bit.ly/BCNA_BCAM_or call BCNA's Helpline on 1800 500 258 between 9:00 am - 5:00 pm AEST Monday to Friday
